The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer remains a leading cause of cancer-related mortality.
• Anaplastic lymphoma kinase (ALK) rearrangements are key drivers in a subset of non-small cell lung carcinoma (NSCLC).
• ALK inhibitors have revolutionized treatment for ALK-positive NSCLC, demonstrating superior efficacy over chemotherapy.

Purpose of the Study:

• To review the clinical success and ongoing development of ALK inhibitors for NSCLC.
• To discuss mechanisms of resistance to ALK inhibitors and emerging therapeutic strategies.
• To highlight challenges in implementing advanced therapies for ALK-rearranged NSCLC.

Main Methods:

• Review of clinical trials and research on ALK inhibitors in NSCLC.
• Analysis of resistance mechanisms and development of next-generation inhibitors.
• Exploration of combination therapies and treatment sequencing.

Main Results:

• First-generation ALK inhibitors (crizotinib, ceritinib, alectinib) are approved and effective first-line treatments.
• Resistance to ALK inhibitors inevitably develops, often leading to brain metastasis.
• Next-generation inhibitors and combination strategies are under development to overcome resistance.

Conclusions:

• Despite significant progress, acquired resistance remains a major challenge in ALK-positive NSCLC treatment.
• Future therapeutic approaches will likely involve sequential or combination therapies targeting ALK and other pathways.
• Addressing high treatment costs and potential toxicities of combination therapies is crucial for optimal patient outcomes.